Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214160 · ClinicalTrials.gov registry record · Phase 2
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies
A Phase 2 study, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT02214160 is a Phase 2 study that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 94 participants.
The verdict
NCT02214160, a Phase 2 study, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the long-term safety and efficacy of UX007 in participants with LC-FAOD. The secondary objectives of this study are to evaluate the effect of UX007 on energy metabolism in LC-FAOD and evaluate the impact of UX007 on clinical events associated with LC-FAOD.
Interventions
- DRUG UX007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2014-12-09 |
| Est. Completion | 2020-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214160
The ClinicalTrials.gov registry entry for NCT02214160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UX007 is the first listed.
NCT02214160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214160 about?
NCT02214160 is a clinical study titled "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies". The primary objective of this study is to evaluate the long-term safety and efficacy of UX007 in participants with LC-FAOD. The secondary objectives of this study are to evaluate the effect of UX007 on energy metabolism in LC-FAOD and evaluate the impact of UX007 on clinical events associated with L...
What is the current status of trial NCT02214160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2014-12-09. Estimated completion is 2020-12-03.
What interventions are being tested in trial NCT02214160?
The interventions under investigation include: UX007 (DRUG).
Who is sponsoring clinical trial NCT02214160?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.